---
title: "Urate-Lowering Therapy"
alias: Chronic Treatment for Gout
slug: "urate-lowering-therapy"
date: "2023-08-05"
enableToc: false
tags:
  - building
---

> [!info]
>
> ðŸŒ± ä¾†è‡ª: [[gout]]

# Urate-Lowering Therapy

- **Allopurinol (PO)**

  - Mechanism: Xanthine oxidase inhibitor
  - Comments: 1st line; adjust starting dose in CKD; titrate â†‘ q2-5wk; a/w rash, hypersensitivity syndrome (see below), BM suppression (avoid w/ AZA/6-MP), diarrhea, N/V, hepatitis; monitor CBC, LFTâ€™s; not nephrotoxic; max dose = 800 mg/d

- **Febuxostat (PO)**

  - Mechanism: Nonpurine xanthine oxidase inhibitor
  - Comments: 2nd line; use if allopurinol intolerant; a/w â†‘ LFT, rash, arthralgias, N/V; avoid w/ AZA/6-MP (BM suppress); start 40 mg, max dose = 120 mg/d

- **Pegloticase (IV)**

  - Mechanism: Recombinant uricase
  - Comments: For refractory tophaceous gout; infusion reactions (including anaphylaxis); Ab formation may limit use (JAMA 2011;306:711); avoid w/ G6PD deficiency

- **Probenecid (PO)**
  - Mechanism: Uricosuric
  - Comments: Rarely used; risk of urolithiasis

Note: PO stands for oral administration, and IV stands for intravenous administration. The "a/w" in the comments indicates "associated with."
